Pfizer Inc and BioNTech's new proposal with the European Union includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled COVID-19 doses, the Financial Times reported on Sunday.
The revised contract would allow the EU to upgrade to newer vaccines tailored to any future COVID-19 variants, the report added, citing people close to negotiations.
Comments
Comments are closed.